TPST · Tempest Therapeutics, Inc. · Financials
$0.81
+0.01 (+0.63%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We expect that our existing cash and cash equivalents will fund our projected operating expense requirements through less than 12 months from the date our consolidated financial statements were available to be issued. Accordingly, there is substantial doubt regarding our ability to continue as a going concern for a period of 12 months from the date of the issuance of the Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 13, 2026
Market Cap
$12.28M
Shares
14.81M
Volume · Oct 2
2.27M
Avg daily vol (3M)
2.59M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$295K
-54.8%
FY2017
Net Income
-$26.26M
+37.2%
FY2025
Gross Margin
-167.8%
+559.3pp
FY2017
Operating Margin
-28585.08%
-16179pp
FY2017
Diluted EPS
-$6.33
+67.5%
FY2025
Operating Cash Flow
-$26.82M
+18.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $295K | — | — | — | — | — | — | — | — | $295K | $653K | $277K | $0 | $0 | — | — | |
| $428K | — | — | — | — | — | — | — | — | $790K | $5.4M | $2.25M | $0 | $0 | — | — | |
| -$133K | — | — | — | — | — | — | — | — | -$495K | -$4.75M | -$1.97M | $0 | $0 | — | — | |
| — | — | — | — | — | — | — | — | — | -167.8% | -727.11% | -711.91% | — | — | — | — | |
| $3.04M | $12.61M | $28.48M | $17.5M | $22.53M | $17.17M | $14.39M | $27.84M | $14.43M | $18.34M | $21.64M | $18.43M | $21.78M | $15.8M | $6.32M | — | |
| $15.42M | $13.97M | $13.55M | $11.66M | $12.11M | $9.82M | $4.91M | $17.56M | $8.69M | $5.96M | — | — | — | $13.33M | $7.21M | — | |
| $15.85M | — | — | — | — | — | — | — | — | $27.74M | $49.22M | $51.59M | $26.15M | $13.33M | $7.21M | — | |
| $919K | — | — | — | — | — | — | — | — | $1.65M | $2.24M | $1.29M | $450K | $231K | $93K | — | |
| $3.83M | — | — | — | — | — | — | — | — | $4.03M | $5.4M | $0 | $0 | — | — | — | |
| $30.36M | — | — | — | — | — | — | — | — | $50.9M | $81.67M | $72.28M | $47.93M | $29.13M | $13.53M | — | |
| -$40.64M | -$26.58M | -$42.03M | -$29.16M | -$34.64M | -$26.99M | -$19.3M | -$45.4M | -$26.87M | -$84.33M | -$81.01M | -$72M | -$47.93M | -$29.13M | -$13.53M | — | |
| — | — | — | — | — | — | — | — | — | -28585.08% | -12406.13% | -25992.42% | — | — | — | — | |
| -$58.66M | — | — | — | — | — | — | — | — | -$82.68M | -$78.77M | -$70.71M | -$47.48M | -$28.9M | -$13.44M | — | |
| $0 | $207K | $1.32M | $1.45M | $1.62M | $1.28M | $0 | — | $134K | $288K | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$126K | $90K | $19K | — | |
| $170K | $313K | $183K | -$334K | -$1.07M | -$1.32M | $90K | — | — | -$36K | -$164K | -$20K | $122K | $0 | — | — | |
| -$9000 | — | — | — | — | — | — | — | — | -$1.02M | -$1.54M | -$1.56M | -$1.58M | $0 | — | — | |
| -$29.25M | — | — | — | — | — | — | — | — | -$50.91M | -$82.06M | -$73.14M | -$49.52M | -$29.04M | — | — | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | $67K | $201K | $75K | $0 | $0 | $0 | $0 | |
| -$40.47M | -$26.26M | -$41.84M | -$29.49M | -$35.71M | -$28.3M | -$19.21M | -$44.57M | -$27.19M | -$84.58M | -$82.26M | -$73.22M | -$49.52M | -$29.04M | -$13.51M | — | |
| — | — | — | — | — | — | — | — | — | -28670.51% | -12597.24% | -26432.85% | — | — | — | — | |
| — | — | — | — | — | — | — | $0 | $15K | -$8000 | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | -$50.98M | -$82.26M | -$73.22M | -$49.52M | -$29.04M | -$13.51M | — | |
| — | — | — | — | — | — | -$36.12M | -$44.55M | -$27.05M | -$50.94M | -$82.15M | -$73.36M | -$49.56M | -$29.03M | -$13.52M | — | |
| USD/shares | -$3.97 | -$6.33 | -$19.50 | -$24.83 | -$40.17 | -$97.11 | -$533.39 | — | — | — | — | — | — | — | — | — |
| USD/shares | -$3.97 | -$6.33 | -$19.50 | -$24.83 | -$40.17 | -$97.11 | -$533.39 | — | — | — | — | — | — | — | — | — |
| shares | — | 4.15M | 2.15M | 1.19M | 888.38K | 291.56K | 36.01K | 70.29K | 7933.5949 | 1347.8103 | 164.86K | 138.9K | 116.14K | 82.87K | 29.79K | — |
| shares | — | 4.15M | 2.15M | 1.19M | 888.38K | 291.56K | 36.01K | 70.29K | 7933.5949 | 1347.8103 | 164.86K | 138.9K | 116.14K | 82.87K | 29.79K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 1,287,000 | 10-Q filed 2026-08-13 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 6,273,000 | 10-Q filed 2026-08-13 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.78×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.70×
Peer medians compare against the 225 similar-size Biotechnology companies (of 532 listed).